Metabolic syndrome: Limited significance for clinical practice;Het metabool syndroom: Beperkte meerwaarde voor de klinische praktijk

Nederlands Tijdschrift voor Geneeskunde

Volumn 149, Issue 16, 2005, Pages 855-858

  Dekker, J M ^a   Diamant, M ^b   Nijpels, G ^a   Heine, R J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; TRIACYLGLYCEROL;

BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE; METABOLIC SYNDROME X; OBESITY; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; METABOLIC SYNDROME X; OBESITY;

EID: 17444427095     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
2. World Health Organization (WHO). Definition, diagnosis and classification of diabetes mellitus. Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus. WHO/NCD/NCS/99.2. Genève: WHO; 1999.
3. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-3.
4. Olijhoek JK, Martens FMAC, Banga JD, Visseren FLJ. Het metabool syndroom: een cluster van vasculaire risicofactoren. Ned Tijdschr Geneeskd 2005;149:859-65.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
6. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003;9:237-52.
7. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
8. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
9. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Bonadonna RC, et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care 2003;26:1251-7.
10. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DSJ, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-9.
11. Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu W, et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians. The Strong Heart Study. Diabetes Care 2003;26:861-7.
12. Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedersen TR, et al. 48 Group and the AFCAPS/TexCAPS Research Group. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (48) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004;93:136-41.
13. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. DECODE Study Group. Arch Intern Med 2004;164:1066-76.
14. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004;173: 309-14.
15. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110:1245-50.
16. Rutter MK, Meigs JB, Sullivan LM, D'Agostino sr RB, Wilson PWF. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004;110:380-5.
17. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. San Antonio Heart Study. Circulation 2004;110:1251-7.
18. Dekker JM, Girman CJ, Rhodes T, Nijpels G, Stehouwer CDA, Bouter LM, et al. Metabolic syndrome is associated with fatal cardiovascular disease in men and non-fatal cardiovascular disease in women. The Hoorn Study. Diabetologia 2003;46(Suppl 2):A76-210.
19. Hills SA, Balkau B, Coppack SW, Dekker JM, Mari A, Natali A, et al. The EGIR-RISC Study (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and objectives. EGIR-RISC Study Group. Diabetologia 2004;47:566-70.
20. Kerstens MN, Wolffenbuttel BHR, Dullaart RPF. Weefselspecifieke veranderingen in het cortisolmetabolisme en hun mogelijke rol in het metabool syndroom. Ned Tijdschr Geneeskd 2005;149:871-6.
21. Serné EH, Jongh RT de, IJzerman RG, Stehouwer CDA. Microvasculaire disfunctie als verklaring van het metabool syndroom. Ned Tijdschr Geneeskd 2005;149:866-70.
22. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
23. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004;27:2676-81.